Introduction {#S0001}
============

The chronic nature of epilepsy and long-term pharmacotherapy focus concern on patients' safety. Since 1990, the number of approved antiepileptic drugs (AEDs) has been increasing progressively, and the development of a newer generation of AEDs continues. Monotherapy is preferred over polytherapy and, whenever possible, therapy adapted to the needs of individual patients is chosen \[[@CIT0001], [@CIT0002]\]. Although newer AEDs are not considered more efficacious than conventional anticonvulsants, they may be better tolerated \[[@CIT0003]--[@CIT0007]\].

Tolerability profile is an important factor determining the choice of appropriate AED for an individual patient. However, it is known that the spontaneous reporting of adverse events (AEs) leads to underestimation of their diversity and frequency \[[@CIT0008]\]. Evaluation of antiepileptic drug therapy with standardized questionnaires, including lists of AEs, increases their detection and allows one to understand individual patients' problems and optimize their therapy \[[@CIT0009]--[@CIT0012]\].

This study (adverse Event Scale in Patients with Epilepsy Study -- aESCAPE; NCT00394927) aimed to assess the rate and distribution of neurological and systemic AEs related to antiepileptic treatment with older and newer AEDs, as well as to monotherapy and polytherapy. The overall results of the aESCAPE study, performed in 6 European countries, have been described by Cramer *et al*. \[[@CIT0013]\]. This report presents the results of analysis reflecting the prevalence and types of AEs associated with AEDs use, and reasons for treatment modification in the population of Polish patients with epilepsy enrolled in the aESCAPE study.

Material and methods {#S0002}
====================

The aESCAPE (NCT00394927) study was an observational, cross-sectional, multicentre, multicounty, surveillance, in-label study carried out in the Czech Republic, Germany, Italy, Poland, Romania and Spain in 2007 \[[@CIT0013]\]. All patients provided written informed consent before the study. The study was approved by the Independent Ethics Committee. In Poland, 15 sites participated in patient recruitment. The methodology of the study was described in detail by Cramer *et al*. \[[@CIT0013]\].

The AE experiences of patients with epilepsy were evaluated with a structured questionnaire developed for the longitudinal Veterans Administration Cooperative Studies (Neurological and Systemic Adverse Event Rating Scales \[N&SAERS\]) \[[@CIT0014]\], translated from English to Polish. Physicians completed the questionnaire during one study visit, on the basis of one structured interview, neurological and physical assessment during the visit, and medical history files. The primary outcome variable of the study was the percentage of patients reporting ≥ 1 AE(s) (based on N&SAERS). Secondary outcome variables were: prevalence of each type of AE, patient and epilepsy characteristics, and reasons for treatment modifications.

Patients aged \> 4 years, diagnosed with epilepsy, with stable treatment with one or two AED(s) for ≥ 3 months, could participate in the survey. Severe or uncontrolled symptomatic chronic illness concomitant to epilepsy excluded patients from the study. The choice of antiepileptic medication was not determined by the study protocol. Drugs used were classified into two categories: 1) newer AEDs: gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), tiagabine (TGB), topiramate (TPM), or any combination of these; 2) older AEDs: carbamazepine (CBZ), clobazam (CLB), clonazepam (CZP), phenobarbital (PB), phenytoin (PHT), valproate (VPA) and any combination of two older AEDs or a combination of one older and one newer AED. All AEDs had to be used in accordance with the Polish marketing authorization valid at the time of the study.

Because of the explanatory and cross-sectional nature of the aESCAPE study (NCT00394927), a formal sample size calculation was not performed. For the analysis, two ways of patient grouping were defined, depending on the type and number of concomitant AEDs used: patients receiving only newer AEDs vs. those receiving older AEDs (including a combination of one older and one newer AED); and patients on monotherapy versus those receiving polytherapy. Percentages of patients who reported ≥ 1 AE(s), as described in N&SAERS, are presented. A logistic regression model on the presence of ≥ 1 AE(s) in terms of type of treatment (polytherapy vs. monotherapy, newer vs. older AEDs) was performed. Descriptive statistics for the decision to modify treatment at the study visit are presented. Logistic regression models on the proportion of patients modifying treatment were performed, including a number of explanatory variables: type of treatment (polytherapy vs. monotherapy, newer vs. older AEDs), presence vs. absence of AEs, generalized vs. not generalized seizures, and time since the latest seizure (≥ 1 vs. \< 1 year ago).

Results {#S0003}
=======

Patients and antiepileptic drugs {#S20004}
--------------------------------

In Poland, 309 patients were recruited. They constituted 30.9% of all patients participating in the aESCAPE study (*n* = 1019). Demographic and clinical characteristics were largely similar in the analyzed groups. Partial-onset seizures (POS) were diagnosed in 73.5% of the patients and 24.3% of the patients were diagnosed with primary generalized seizures (PGS) ([Table I](#T0001){ref-type="table"}). 61% of the patients (*n* = 188) were on monotherapy, among whom 70% (*n* = 132) were treated with an older AED. Out of the patients on a polytherapy regimen (*n* = 121), 75.2% were on a combination of older and newer AEDs, 8.2% used a combination of two older AEDs, and 16.5% used two newer AEDs ([Table I](#T0001){ref-type="table"}). Overall, in the Polish population, patients were on a stable dose regimen for a median of 10 months at the time of the study. The median time since the last seizure was 183 days. Polytherapy regimen was associated with a 2.5 times shorter period since the last seizure than the period generally observed in the overall Polish population ([Table I](#T0001){ref-type="table"}).

###### 

Demographics, epilepsy and treatment characteristics

  Characteristics                                                                                               Overall (*n* = 309)   Newer (*n* = 76)   Older^[a](#TF0001){ref-type="table-fn"}^ (*n* = 233)   Mono (*n* = 188)   Poly (*n* = 121)
  ------------------------------------------------------------------------------------------------------------- --------------------- ------------------ ------------------------------------------------------ ------------------ ------------------
  Gender^[d](#TF0004){ref-type="table-fn"}^                                                                                                                                                                                        
   Female, *n* (%)                                                                                              157 (50.8)            45 (59.2)          112 (48.1)                                             95 (50.5)          62 (51.2)
   Male, *n* (%)                                                                                                151 (48.9)            30 (39.5)          121 (51.9)                                             92 (48.9)          59 (48.8)
  Age \[years\]^[e](#TF0005){ref-type="table-fn"}^                                                                                                                                                                                 
   Mean ± SD                                                                                                    23.92 ±16.72          21.53 ±13.35       24.70 ±17.63                                           21.89 ±16.66       27.02 ±16.41
   Range                                                                                                        4--82                 4--73              4--82                                                  4--79              4--82
  Age at onset \[years\]^[e](#TF0005){ref-type="table-fn"}^                                                                                                                                                                        
   Mean ± SD                                                                                                    13.76 ±13.46          12.57 ±10.69       14.15 ±14.24                                           14.34 ±13.67       12.88 ±13.12
   Range                                                                                                        1--78                 1--78              1--78                                                  1--72              1--78
  Duration since last seizure \[days\]^[b](#TF0002){ref-type="table-fn"},\ [e](#TF0005){ref-type="table-fn"}^                                                                                                                      
   Median~(Q1--Q3)~                                                                                             183~(30--517)~        183~(32--365)~     183~(25--525)~                                         274~(84--660)~     66~(10--216)~
  Duration since last treatment modification \[months\]^[b](#TF0002){ref-type="table-fn"}^                                                                                                                                         
   Median~(Q1--Q3)~                                                                                             10~(5--19)~           8~(5--15)~         11~(5--22)~                                            11~(6--22)~        8~(5--18)~
  Type of seizure^[c](#TF0003){ref-type="table-fn"},\ [f](#TF0006){ref-type="table-fn"}^, *n* (%)                                                                                                                                  
   POS only                                                                                                     227 (73.5)            58 (76.3)          169 (72.5)                                             129 (68.6)         98 (81.0)
   PGS only                                                                                                     75 (24.3)             17 (22.4)          58 (24.9)                                              55 (29.3)          20 (16.5)
   POS & PGS                                                                                                    3 (1.0)               --                 3 (1.3)                                                --                 3 (2.5)
  AED by medication, *n* (%)                                                                                                                                                                                                       
   CBZ                                                                                                          86 (27.8)             --                 86 (26.9)                                              50 (26.6)          36 (29.8)
   CLN                                                                                                          3 (1.0)               --                 3 (1.3)                                                --                 3 (2.5)
   GBP                                                                                                          13 (4.2)              7 (9.2)            6 (2.6)                                                3 (1.6)            10 (8.3)
   LTG                                                                                                          63 (20.4)             29 (38.2)          34 (14.6)                                              20 (10.6)          43 (35.5)
   LEV                                                                                                          16 (5.2)              6 (7.9)            10 (4.3)                                               2 (1.1)            14 (11.6)
   OXC                                                                                                          49 (15.9)             33 (43.4)          16 (6.9)                                               22 (22.3)          27 (22.3)
   PB                                                                                                           2 (0.6)               --                 2 (0.9)                                                --                 2 (1.7)
    PHT                                                                                                         3 (1.0)               --                 3 (1.3)                                                2 (1.1)            1 (0.8)
   TGB                                                                                                          10 (3.2)              5 (6.6)            5 (2.1)                                                1 (0.5)            9 (7.4)
   TPM                                                                                                          36 (11.7)             16 (21.1)          20 (8.6)                                               8 (4.3)            28 (23.1)
   VPA                                                                                                          149 (48.2)            --                 149 (48.2)                                             80 (42.6)          69 (57.0)
  AED by group, *n* (%)                                                                                                                                                                                                            
   1 older                                                                                                      132 (42.7)            --                 132 (56.6)                                             132 (70.2)         --
   1 newer                                                                                                      56 (18.1)             56 (73.7)          --                                                     56 (29.8)          --
   2 older                                                                                                      10 (3.2)              --                 10 (4.3)                                               --                 10 (8.3)
   2 newer                                                                                                      20 (6.5)              20 (26.3)          --                                                     --                 20 (16.5)
   1 older + 1 newer                                                                                            91 (29.4)             --                 91 (39.0)                                              --                 91 (75.2)

Also includes patients on 1 newer and 1 older AED

Median (Q1 -- the first quartile -- Q3 -- the third quartile)

Types of seizures, POS -- partial onset seizures including simple partial seizures, complex partial seizures, partial onset seizures with secondary generalization alone and in combinations; PGS -- primarily generalized seizures including absence, myoclonic, clonic, tonic-clonic, atonic seizures alone and in combination

Gender data were missing for one patient

Age and age at epilepsy onset data were missing for 3 patients

Type of seizure data were missing for 4 patients

Almost half of the patients were treated with VPA (48.2%). Commonly used AEDs in monotherapy were: VPA (42.6%), CBZ (26.6%), OXC (11.7%), LTG (10.6%), and in combination therapy: LTG + VPA (20.7%), OXC + VPA (11.6%), TPM + VPA (9.1%).

Prevalence and types of adverse events {#S20005}
--------------------------------------

In the Polish population, 73.8% of patients reported ≥ 1 AE(s) (66% reported ≥ 1 neurological AE(s), 41.4% reported ≥ 1 systemic AE(s)) ([Figure 1](#F0001){ref-type="fig"}). A slightly higher percentage of Polish patients on older AED(s) reported ≥ 1 AE(s) in comparison with patients on newer AED(s) OR = 0.59, 95% CI: 0.31--1.14, *p* = 0.1182) ([Figure 1](#F0001){ref-type="fig"}). The percentage of patients reporting ≥ 1 AE(s) was similar in monotherapy (71.3%) and polytherapy (77.7%) groups (OR = 1.15, 95% CI: 0.61--2.15, *p* = 0.6744).

![Patients reporting ≥ 1 AE, ≥ 1 neurological AE, ≥ 1 systemic AE\
\*Also includes patients on 1 newer and 1 older AED](AMS-9-21680-g001){#F0001}

Overall, the most commonly reported AEs (\> 10% patients) were: disturbances in cognitive function, psychological problems, sedation, gain or loss of weight, headache, tremor, gastrointestinal complaints and dizziness ([Table II](#T0002){ref-type="table"}). The following AEs were reported more frequently by patients on older AED(s) or a combination of older and newer AED(s) than by patients on newer AED(s): disturbances in cognitive function, sedation and gastrointestinal problems ([Table II](#T0002){ref-type="table"}). Polytherapy, as compared with monotherapy, was to a greater extent associated with cognitive function disturbance, sedation, tremor, ataxia, dysarthria, diplopia and gastrointestinal problems ([Table II](#T0002){ref-type="table"}).

###### 

Incidence (%) of AEs reported by ≥ 5% of patients in any group

  Parameter                                                     Overall (*n* = 309)   Newer (*n* = 76)   Older^[a](#TF0007){ref-type="table-fn"}^ (*n* = 233)   Mono (*n* = 188)   Poly (*n* = 121)
  ------------------------------------------------------------- --------------------- ------------------ ------------------------------------------------------ ------------------ --------------------------------------------
  Neurological AE \[%\]                                                                                                                                                            
   Cognitive function disturbance                               40.5                  30.3               43.8[\*\*](#TF0010){ref-type="table-fn"}               31.4               54.5[\*\*\*](#TF0011){ref-type="table-fn"}
   Psychological problems^[b](#TF0008){ref-type="table-fn"}^    36.2                  31.6               37.8                                                   32.4               42.1
   Sedation                                                     32.7                  22.4               36.1[\*\*](#TF0010){ref-type="table-fn"}               28.2               39.7[\*\*](#TF0010){ref-type="table-fn"}
   Headache                                                     18.4                  12.0               13.6                                                   14.4               12.4
   Tremor                                                       13.6                  9.2                15.0                                                   8.5                21.5[\*\*\*](#TF0011){ref-type="table-fn"}
   Dizziness                                                    10.4                  6.6                11.6                                                   8.0                14.0
   Ataxia                                                       4.5                   2.6                5.2                                                    2.7                7.4[\*\*](#TF0010){ref-type="table-fn"}
   Dysarthria                                                   3.6                   6.6                2.6                                                    0.5                8.3[\*\*\*](#TF0011){ref-type="table-fn"}
   Diplopia                                                     3.2                   6.6                2.1                                                    1.6                5.8[\*\*](#TF0010){ref-type="table-fn"}
  Systemic AE \[%\]                                                                                                                                                                
   Gain or loss of weight                                       19.4                  15.8               20.6                                                   19.7               19.0
   GI problems                                                  12.0                  2.6                15.0[\*\*\*](#TF0011){ref-type="table-fn"}             8.5                15.4[\*\*](#TF0010){ref-type="table-fn"}
   Arthralgia                                                   8.4                   5.3                9.4                                                    10.1               5.8
   Changes in hair quantity and texture                         7.8                   5.3                8.6                                                    6.9                9.1
   Lack of menstrual cycle^[c](#TF0009){ref-type="table-fn"}^   5.5                   9.2                4.3                                                    4.8                6.6

Also includes patients on 1 newer and 1 older AED

Depression, tension/agitation, anger/hostility, vigor/excitability, fatigue/apathy, confusion/thought disorder

If applicable

p \< 0.05

p \< 0.01

Treatment modifications {#S20006}
-----------------------

The decision regarding treatment modification was made during the study visit for 22.3% of the patients (15.9% -- dose change and 6.5% -- AED change). Treatment modification was introduced less often for patients on newer AEDs (13.2%) or for patients on monotherapy (17.0%) than for those on older AEDs (25.3%) or for patients on polytherapy (30.6%), respectively ([Figure 2](#F0002){ref-type="fig"}). The main reasons for changing AEDs were lack of efficacy (50%), or AEs (30%). The main reasons for changing drug doses were lack of efficacy (46.9%), absence of seizures (24.5%), or AEs (20.5%) (data not shown).

![Reason for treatment modification in patients whose treatment was changed during the study visit by AED group\
\*Also includes patients on 1 newer and 1 older AED](AMS-9-21680-g002){#F0002}

During the study visit, the treatment was more likely to be modified for patients on polytherapy than for patients on monotherapy (OR = 1.98, 95% CI: 1.07--3.66, *p* = 0.029). Logistic regression analysis showed that the likelihood of physicians modifying treatment for patients who had been seizure-free for ≥ 1 year (in 15.0% of cases) was smaller than in the case of patients who had had a seizure \< 1 year ago (in 25.8% of cases) (OR = 0.53, 95% CI: 0.27--1.06, *p* = 0.07). Presence of AEs (≥ 1 AE(s) vs. no AE, OR = 0.71, 95% CI: 0.36--1.42, *p* \> 0.3) and treatment with newer AEDs (never vs. older AEDs, OR = 0.64, 95% CI: 0.29--1.38, *p* \> 0.2) did not affect the likelihood of treatment modification.

Discussion {#S0007}
==========

Development of the systematic screening and rating scale of AEs to assess AED safety has facilitated the identification of AEs \[[@CIT0009]--[@CIT0012]\], which, by leading to treatment modification, could improve tolerability. Standardized questionnaires for patients and physicians seem to act as detailed tools for precise detection and monitoring of undesired effects of AEDs \[[@CIT0010], [@CIT0014]\]. According to Carreno *et al*. \[[@CIT0009]\], the use of a questionnaire, as compared with spontaneous reporting, has increased reporting of AEs about twofold. Canevini *et al*. \[[@CIT0015]\] indicated that the use of the Adverse Event Profile questionnaire, as compared with spontaneous reporting, has increased reporting of AEs 13 times. As also shown in previous studies \[[@CIT0009], [@CIT0012]\], about 2/3 of patients reported AEs after having been provided with a checklist, which is consistent with the results obtained in the subpopulation of Polish patients enrolled in the aESCAPE study.

Newer AEDs are used when initial therapy with older AEDs has failed. Many Polish physicians use VPA and CBZ (for almost 1/2 and 1/4 of patients, respectively) on the basis of extensive clinical experience, and because they are devoted to VPA as a drug having a broad spectrum of efficacy \[[@CIT0016]\]. In this analysis, newer AEDs were used by 55% of patients, mainly in combinations with older AEDs ([Table I](#T0001){ref-type="table"}).

In general, newer AEDs appear to be better tolerated than older AEDs \[[@CIT0003]--[@CIT0007]\]. The overall results of the aESCAPE study reported by Cramer *et al*. \[[@CIT0013]\] indicated that patients taking newer AEDs report ≥ 1 AE(s) much less frequently than patients on older AEDs (OR = 0.64, *p* = 0.008). In the Polish subpopulation the percentage of patients reporting ≥ 1 AE(s) was slightly higher in the group using at least 1 older AED than in the group using newer AED(s) ([Figure 1](#F0001){ref-type="fig"}) (OR = 0.59, *p* = 0.118), which is in accordance with previous observations \[[@CIT0003]--[@CIT0009]\] and with the overall results of the aESCAPE study \[[@CIT0013]\]; however, statistical significance was not reached, possibly due to the small sample size.

Previous studies suggested that polytherapy increases the probability of AEs \[[@CIT0004], [@CIT0012]\] and reduction or elimination of polytherapy may be the way to minimize the number of AEs \[[@CIT0017]\]. Polish patients using two AEDs reported ≥ 1 AE(s) slightly more frequently than those on monotherapy ([Figure 1](#F0001){ref-type="fig"}) (OR = 1.15, *p* = 0.674). One of the limitations of our study is that the population of patients on polytherapy was composed of persons using no more than two AEDs. In fact, dual therapy may not reflect common problems of polytherapy in which many patients take three or more AEDs. According to the results of a previous national study, 11.8% of patients used ≥ 3 AEDs \[[@CIT0018]\]. In the Polish subpopulation of the aESCAPE study, most of the patients on monotherapy (70.2%) and almost all patients on polytherapy (83.5%) were using older AED(s). A recent cross-sectional study which was performed in Italy, and in which AE profiles of refractory patients on mono- or polytherapy were compared, did not show a difference in the burden of AEs, even though the most prevalent medications in both groups were newer AEDs \[[@CIT0015]\].

We observed that cognitive dysfunction and sedation were reported much more frequently by patients treated with older AEDs or on polytherapy than by patients treated with newer AEDs or on monotherapy. These AEs were the most frequent reasons for patient complaints in previous studies \[[@CIT0012], [@CIT0019]\]. It should be noted that in a previous study \[[@CIT0009]\], subjective complaints, such as cognitive and mood problems and tiredness, were more frequently reported via checklist than spontaneously, which emphasizes the importance of a systematic approach for detection of these AEs. It is worth noting that patients on polytherapy reported neurotoxicity-related AEs, such as tremor, dysarthria, diplopia and ataxia, more frequently than patients on monotherapy. These AEs are difficult to avoid when using polytherapy \[[@CIT0020]\], which was also reflected in the study by Carreno *et al*. \[[@CIT0009]\]: patients using polytherapy reported tremor, speech difficulties, diplopia and blurred vision, walking difficulties and stumbling much more frequently than patients on monotherapy.

Physicians in Poland decided to modify treatment for 22.3% of patients. This is similar to the results obtained in the overall aESCAPE population (22.8%) \[[@CIT0013]\] and those reported by Carreno *et al*. (26.4%) \[[@CIT0009]\]. While adequate seizure control in making clinical decisions was very important, lack of efficacy was the main reason for treatment modifications in the Polish population. Lack of efficacy was the most important reason for both AED change and dose modification. Additionally, time since latest seizure shorter than 1 year was found to be a predictor of treatment modification (OR = 0.53, *p* = 0.07), which is consistent with the findings of Cramer *et al*. \[[@CIT0013]\] concerning the overall aESCAPE population (OR = 0.39, *p* \< 0.001). Indeed, achieving a seizure-free state may improve life quality to the level observed in the general population \[[@CIT0021]\]. Lack of efficacy was a reason for almost 50% of treatment modifications; AEs accounted for about 23%. This is similar to the results obtained by Carreno *et al*. \[[@CIT0009]\], where about 60% of treatment changes were carried out due to inadequate seizure control and 23% due to AEs. The overall results of the aESCAPE study have shown that lack of efficacy and AEs accounted for 1/3 of treatment modifications \[[@CIT0013]\]. It should be noted that median time since the latest seizure was shorter in the Polish subpopulation (6.5 months) than median time observed in the overall aESCAPE population (7.7 months), which may partially explain higher attention of Polish doctors' to treatment efficacy issues. Moreover, the strongest predictor of treatment modification was a polytherapy regimen (OR = 1.98, *p* = 0.029) where patients had shorter time since the latest seizure ([Table I](#T0001){ref-type="table"}), which may also account for the observed frequent treatment modifications attributed to the lack of efficacy. Thus, treatment tolerability has not been found to be a factor influencing treatment modification in Polish patients (OR = 0.71, *p* \> 0.3). However, in the European aESCAPE study, a trend to modify treatment in the case of AE occurrence was observed (OR = 1.48, *p* = 0.055) \[[@CIT0013]\]. Interestingly, as regards the Polish patients treated exclusively with newer AED(s), no treatment adjustments were suggested during the study visit due to AEs. However, due to the non-randomized and cross-sectional character of the study, we cannot attribute it to newer AED(s) use, since other factors (e.g. severity of AEs) may also be important. Absence of seizures was a frequent reason (20.3%) for treatment modification. Recent results indicate that such an intervention results in the improvement of life quality \[[@CIT0022]\].

Limitations to these analyses include the non-randomized, cross-sectional study design. Since the treatment was not randomly assigned, baseline differences in disease state and possibly other factors, which could be related to the primary outcome variable, were more likely to occur. Observations made at one point in time do not provide information about a sequence of events (which is particularly important as regards studying chronic illness) and follow-up. In order to avoid overestimation of newer AEDs' usefulness and to account for heterogeneity of the patient population with different treatment regimens, the patients treated with a combination of one newer and one older AED were classified in the group of "older AEDs". Analyses are also limited by studying only the Polish patients enrolled in the overall aESCAPE study. The small number of patients taking newer AEDs did not allow for adequate comparisons for some AEDs. In addition, the fact that almost half of the patients were taking VPA alone or in combination overweighed analyses toward that AED.

Although the Polish subpopulation analysis results revealed a high number of patient complaints in the course of epilepsy treatment, only a small part of them required treatment adjustment due to AE(s) occurrence. Treatment modifications were mainly related to lack of efficacy and concerned mostly patients on polytherapy. Results from the Polish subpopulation of the aESCAPE study suggest that more resistant clinical forms of epilepsy occur as the reasons of treatment adjustment more frequently than the AED tolerability issues. This study demonstrated that by using the N&SAERS, physicians can quickly and easily determine the scope of AEDs' adverse effects during routine visits \[[@CIT0013], [@CIT0014], [@CIT0019]\]. The N&SAERS provides a structured approach to monitoring a wide spectrum of possible AEs in the course of epilepsy treatment.
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